Antibodies as Drugs: Engineering and Computational Tools Enabling Clinical Advances

January 1-4, 2026 | Location to be Determined
Scientific Organizers: Paul Carter, John R. Desjarlais and E. Sally Ward

  In Person
  On Demand

January 1-4, 2026 | Location to be Determined
Scientific Organizers: Paul Carter, John R. Desjarlais and E. Sally Ward

Available Formats:   = In Person     = On Demand
Thursday, January 1, 2026
Registration
4:00–8:00 PM
Welcome Mixer
6:00–8:00 PM
Friday, January 2, 2026
Breakfast
7:00–8:00 AM
Keynote Address
8:00–9:00 AM
David Baker †, University of Washington
Computational Design of Proteins for Therapeutic Applications
Plenary AM
9:00–11:15 AM
Charlotte Deane †, Exscientia and University of Oxford
Computational Tools for Antibody Immunogenicity and Developability Risk Assessment
Peter S. Kim †, Stanford University
Unsupervised Evolution of Protein and Antibody Complexes with a Structure-Informed Language Model
Peyton Greenside †, BigHat Biosciences
Combining Active Learning with a Rapid Synthetic Biology Platform to Design Therapeutic Antibodies
Short Talk(s) Chosen from Abstracts
Coffee Break
9:30–9:50 AM
Poster Setup
11:15–1:00 PM
On Own for Lunch
11:15–5:00 PM
Poster Viewing
1:00–10:00 PM
Coffee Available
4:30–5:00 PM
Plenary PM
5:00–7:00 PM
Naoka Hironiwa †, Chugai Pharmabody Research
Antibody Activation using Ca2+ or ATP-Switches
Thomas Thisted †, Sensei Biotherapeutics
VISTA Checkpoint Inhibition by pH-Selective Antibody
Tommy DiRaimondo †, Janux Therapeutics
Protease-Activated anti-PSMA T Cell Engager, JANX-007
Short Talk(s) Chosen from Abstracts
Social Hour with Lite Bites
7:00–8:00 PM
Posters
7:30–10:00 PM
Saturday, January 3, 2026
Breakfast
7:00–8:00 AM
Plenary AM
8:00–11:00 AM
Jo L. Viney †, Seismic Therapeutic
AI/ML for Biologics Drug Discovery for Immunology
Jo L. Viney †, Seismic Therapeutic
AI/ML for Biologics Drug Discovery for Immunology
James A. Wells †, University of California, San Francisco
Degraders to Attack the Cancer Surfaceomewell
Paul Carter, Genentech, Inc.
Engineering Antibodies to Improve High Concentration Properties for Subcutaneous Delivery
E. Sally Ward, University of Southampton
Targeting Subcellular Trafficking for the Generation of Therapeutics
Short Talk(s) Chosen from Abstracts
Coffee Break
9:00–9:20 AM
Poster Setup
11:00–1:00 PM
On Own for Lunch
11:00–5:00 PM
Poster Viewing
1:00–10:00 PM
Coffee Available
4:30–5:00 PM
Plenary PM
5:00–7:00 PM
Elaine Hurt †, AstraZeneca
Lessons Learned from 30 Years of ADC Development
Greg Thurber †, University of Michigan
Optimizing ADC Delivery by Avidity/Affinity Tuning
Arthur A. Levin †, Avidity Biosciences
Antibody-Oligonucleotide Conjugates
Short Talk(s) Chosen from Abstracts
Social Hour with Lite Bites
7:00–8:00 PM
Posters
7:30–10:00 PM
Sunday, January 4, 2026
Breakfast
7:00–8:00 AM
Plenary AM
8:00–11:00 AM
Mark S Cragg †, University of Southampton
Tumor Microenvironment Limitations for Classical Immune Effector Functions
Yariv Mazor †, AstraZeneca
Multispecific Antibodies
Coffee Break
9:00–9:20 AM
On Own for Lunch
11:00–5:00 PM
Coffee Available
4:30–5:00 PM
Plenary PM
5:00–6:45 PM
James E. Crowe, Jr. †, Vanderbilt University Medical Center
Anti-Corona Virus Antibodies
Plenary
6:45–7:00 PM
Social Hour with Lite Bites
7:00–8:00 PM
Entertainment
8:00–11:00 PM
Cash Bar
8:00–11:00 PM
Monday, January 5, 2026
Departure
12:00–11:59 PM

Subscribe for Updates